596 related articles for article (PubMed ID: 9350917)
1. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
Weber C; Erl W; Weber KS; Weber PC
J Am Coll Cardiol; 1997 Nov; 30(5):1212-7. PubMed ID: 9350917
[TBL] [Abstract][Full Text] [Related]
2. Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions.
Weber C; Erl W; Weber KS; Weber PC
Clin Chem Lab Med; 1999 Mar; 37(3):243-51. PubMed ID: 10353467
[TBL] [Abstract][Full Text] [Related]
3. HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
Teupser D; Bruegel M; Stein O; Stein Y; Thiery J
Biochem Biophys Res Commun; 2001 Dec; 289(4):838-44. PubMed ID: 11735122
[TBL] [Abstract][Full Text] [Related]
4. Increased transforming growth factor-beta(1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase inhibition with pravastatin.
Porreca E; Di Febbo C; Baccante G; Di Nisio M; Cuccurullo F
J Am Coll Cardiol; 2002 Jun; 39(11):1752-7. PubMed ID: 12039487
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
6. Transient increase of monocyte adhesion after a single dose of simvastatin.
Erl W; Weber KS; Weber PC; Weber C
Atherosclerosis; 2001 Oct; 158(2):491-3. PubMed ID: 11583731
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Laufs U; La Fata V; Plutzky J; Liao JK
Circulation; 1998 Mar; 97(12):1129-35. PubMed ID: 9537338
[TBL] [Abstract][Full Text] [Related]
8. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
9. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rosenson RS
Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
[TBL] [Abstract][Full Text] [Related]
10. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo.
Han KH; Ryu J; Hong KH; Ko J; Pak YK; Kim JB; Park SW; Kim JJ
Circulation; 2005 Mar; 111(11):1439-47. PubMed ID: 15781755
[TBL] [Abstract][Full Text] [Related]
11. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia.
Serrano CV; Yoshida VM; Venturinelli ML; D'Amico E; Monteiro HP; Ramires JA; da Luz PL
Atherosclerosis; 2001 Aug; 157(2):505-12. PubMed ID: 11472753
[TBL] [Abstract][Full Text] [Related]
12. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Aviram M; Hussein O; Rosenblat M; Schlezinger S; Hayek T; Keidar S
J Cardiovasc Pharmacol; 1998 Jan; 31(1):39-45. PubMed ID: 9456275
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
14. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR
Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307
[TBL] [Abstract][Full Text] [Related]
15. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
Yu L; Qiu S; Genest J
Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
[TBL] [Abstract][Full Text] [Related]
16. Lovastatin induces differentiation of Mono Mac 6 cells.
Weber C; Erl W; Weber PC
Cell Biochem Funct; 1995 Dec; 13(4):273-7. PubMed ID: 8565148
[TBL] [Abstract][Full Text] [Related]
17. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA.
Park HJ; Kong D; Iruela-Arispe L; Begley U; Tang D; Galper JB
Circ Res; 2002 Jul; 91(2):143-50. PubMed ID: 12142347
[TBL] [Abstract][Full Text] [Related]
18. HMG-CoA reductase inhibitors reduce nicotine-induced expression of cellular adhesion molecules in cultured human coronary endothelial cells.
Cirillo P; Pacileo M; De Rosa S; Calabrò P; Gargiulo A; Angri V; Prevete N; Fiorentino I; Ucci G; Sasso L; Petrillo G; Musto D'Amore S; Chiariello M
J Vasc Res; 2007; 44(6):460-70. PubMed ID: 17657162
[TBL] [Abstract][Full Text] [Related]
19. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin.
Cheng H; Rogers JD; Sweany AE; Dobrinska MR; Stein EA; Tate AC; Amin RD; Quan H
Pharm Res; 1992 Dec; 9(12):1629-33. PubMed ID: 1488408
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
